The objective of this RFI is to solicit feedback from industry, academia, and other stakeholders to assist BARDA in identifying, and understand the development maturity of, vaccine platform technologies that (1) are safe and effective across a broad range of different known infectious disease threats and (2) can enable efficient development timelines in response to emerging infectious disease threats.

Respondents do not have to be a member of the RRPV consortium to submit a response for this RFI; however, they must be a member of the consortium to respond to any future request for project proposals (RPP) for this requirement.

RFI submissions should be emailed to rrpv@ati.org by the deadline listed in the RFI. Late submissions will not be considered.

Original RFI Release:

Issued: 26 November 2025

Amendment 1 Issued: 18 December 2025

Due: 30 January 2026 by 1pm EST